ORIONS Money Stocks

[matt24d]

Rexahn Awarded Patent in Europe for Cancer Drug Archexin(R)
Company to initiate Phase IIa clinical trials in Q4 of 2013





ROCKVILLE, Md., Sep 12, 2013 (BUSINESS WIRE) -- Rexahn Pharmaceuticals, Inc. (nyse mkt:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that the European Patent Office has granted the Company a patent, EP 1546180, for its clinical development candidate Archexin(R) and its use for inhibiting the activated form of Akt-1 (phospho-Akt1)for the treatment of cancer.

Having successfully completed a Phase IIa clinical trial of Archexin in metastatic pancreatic cancer, Rexahn has conducted an extensive scientific, clinical and business analysis of other potential indications for additional Phase IIa clinical trials with the drug. Rexahn is now working with key clinical opinion leaders to finalize the design of a Phase IIa clinical trial in a selected tumor type and plans on updating investors on the tumor type selection and Phase IIa trial timeline in the fourth quarter of 2013.

Peter D. Suzdak, Ph.D., Rexahn's Chief Executive Officer commented, "The issuance of this patent in Europe further strengthens our intellectual property estate on Archexin and provides IP protection and an enhanced position for Rexahn in a geography that represents a significant portion of the global oncology treatment market. This comes at a very important time for our Company, as we plan to embark on a new Phase IIa clinical trial for Archexin in the fourth quarter of this year."